News
The Ventana MET (SP44) RxDx assay is FDA-approved for determining MET protein expression in non-squamous NSCLC patients, aiding in Emrelis treatment qualification. Emrelis, a c-Met-targeted therapy, ...
The VENTANA MET (SP44) RxDx Assay detects the MET (also known as c-Met) protein, which is over-expressed in some patients with non-squamous non-small cell lung cancer (NSQ-NSCLC). The MET protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback